OptimizeRx price target lowered to $16 from $19 at Stifel

Stifel analyst David Grossman lowered the firm’s price target on OptimizeRx to $16 from $19 and keeps a Buy rating on the shares after the company reported Q4 results below consensus and gave Q1 and 2023 guidance that was below consensus, citing eroding economic fundamentals that are elongating sales cycles and reducing marketing spending. The company’s guidance is "not unrealistic," but the firm has modeled lower to reflect continued economic uncertainty, the analyst tells investors.